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Background: E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for
operable stage IIB-III melanoma. We tested banked serum specimens from patients in the vaccine arm of E1694 for
prognostic biomarkers.
Methods: Aushon Multiplex Platform was used to quantitate baseline serum levels of 115 analytes from 40 patients.
Least absolute shrinkage and selection operator proportional hazard regression (Lasso PH) was used to select
markers that are most informative for relapse-free survival (RFS) and overall survival (OS). Regular Cox PH models
were then fit with the markers selected by the Lasso PH. Survival receiver operating characteristic (ROC) analysis
was used to evaluate the ability of the models to predict 1-year RFS and 5-year OS.
Results: Four markers that include Tumor Necrosis Factor alpha Receptor II (TNF-RII), Transforming Growth Factor
alpha (TGF-α), Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), and C-reactive protein (CRP) were found to be most
informative for the prediction of OS (high levels correlate with worse prognosis). The dichotomized risk score based
on the four markers could significantly separate the OS curves (p = 0.0005). When using the four-marker PH model
to predict 5-year OS, we achieved an area under the curve (AUC) of 89% (cross validated AUC = 72%). High baseline
TNF-RII was also significantly associated with worse RFS. The RFS with high (above median) TNF-RII was significantly
lower than low TNF-RII (p = 0.01).
Conclusions: The biomarker signature consisting of TNFR-II, TGF-α, TIMP-1 and CRP is significantly prognostic of
survival in patients with high-risk melanoma and warrants further investigation.
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The immune system plays a critical role in surveillance,
suppression, and ultimately the host inflammatory re-
sponse to cancer. The fine balance between inflammation
and immunosuppression in the tumor microenvironment
has been shown to be critical to the balance between ul-
timate tumor resistance or tumor tolerance, especially in
hosts with solid tumors [1]. Recruitment of immune effec-
tors, especially proinflammatory mediators, predicts dur-
able responses and cancer progression free survival [2].* Correspondence: tarhiniaa@upmc.edu
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stated.Melanoma is a solid tumor that is well known to elicit a
strong immune response and as such, has been the focus
of multiple therapies designed to improve the antitumor
immune response through vaccines, adoptive transfer of
tumor-reactive lymphocytes [3], cytokines and monoclonal
antibodies designed to manipulate immune checkpoints
[4,5]. The role of vaccination with proteins and peptides
has been an area of intense interest [6-8], however many
of these studies have been hampered by modest clinical
benefits despite initially promising results [7,9,10]. One of
the mechanisms involved in immune escape by melanoma
cells involves down regulation of the proinflammatory
microenvironment by regulatory T cells (Treg) via the re-
lease of immunosuppressive cytokines such as IL-10 andLtd. This is an Open Access article distributed under the terms of the Creative
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nisms [9,11]. Type II cytokines such as IL-6, TNF-α, IFN-γ
and IL-10 have also been shown to be important regulators
of melanoma immune tolerance and escape [12]. Recent
studies implicate myeloid derived suppressor cells (MDSC)
in the induction of CD8+ T cell tolerance in tumor-bearing
hosts and that appear to be recruited by tumor-derived sol-
uble factors such as TGF-ß1, IL-10, VEGF, GM-CSF, IL-6
and prostaglandin E2 [13]. Evaluation of such biomarkers
in the peripheral blood for their disease prognostic value is
particularly desirable, given the accessibility and the ability
to perform highly standardized assessments that may have
future clinical applications.
High risk melanoma is defined as surgically resectable
AJCC stage IIB-III disease comprising primary tumors be-
tween 2 and 4 mm in Breslow thickness with ulceration,
greater than 4 mm with or without ulceration or primary
tumors with associated evidence of regional lymphatic me-
tastases. For stages IIB-IIC, the 10-year mortality rate
could be as high as 40-60% and for stage III it ranges from
30-70%, depending on the degree of locoregional involve-
ment [14]. The current standard of care management in-
volves definitive surgical resection followed by adjuvant
interferon-α2b (IFN-α) therapy. Studies of high dose IFN-
α (HDI) have yielded significant improvements in overall
survival (OS) and relapse free survival (RFS) but were also
associated with clinically significant adverse events [15].
Identification of significant prognostic markers in this pa-
tient population is a critical area of need that may have
clinical applications and may guide future adjuvant trials.
This may eventually allow us to focus clinical follow up
and adjuvant therapy upon those patients with the highest
mortality risk sparing lower risk patients from unwanted
follow up, treatment toxicity and cost.
The ganglioside GM2-KLH-QS21 (GMK) vaccine is
composed of a highly antigenic molecule expressed on
melanoma cells (GM2), coupled to an adjuvant (QS21) to
promote a robust and lasting inflammatory response [16].
Early studies demonstrated consistent immunogenicity of
the ganglioside vaccine GM2 given with Bacillus Calmette-
Guérin (BCG) as an adjuvant and a trend towards im-
proved RFS when compared to patients vaccinated with
BCG alone. Patients with high titer GM2 antibodies
showed increased survival [17]. To increase immunogen-
icity, GM2 was covalently conjugated with keyhole limpet
hemocyanin (KLH) and the saponin adjuvant QS-21 was
included, significantly increasing the immunogenicity [8],
and supporting the testing of GMK as adjuvant therapy in
high risk surgically resected melanoma patients as was per-
formed in the E1694 trial as compared to HDI [18]. This
study showed that patients treated with HDI had 33% re-
duction in relapse risk compared to those receiving the
GMK vaccine, with a 28% reduction in the risk of death.
Further, another phase III study (EORTC 18961) confirmedthe ineffectiveness of GMK vaccine as adjuvant therapy
versus observation in high risk AJCC stage II melanoma
[19,20]. Taken together, the two studies support the current
view of GMK vaccine as a neutral control with no signifi-
cant impact upon either endpoints of survival or relapse.
In this study nested within the E1694 GMK trial arm, we
identify four markers: C-reactive protein (CRP), Tissue in-
hibitor of Metalloproteinases 1 (TIMP-1), Tumor Necrosis
Factor alpha Receptor II (TNF-RII) and Transforming
Growth Factor alpha (TGF-α) where the linear combination
in the analysis of our model generates a risk score that has
a significant prognostic value for high risk melanoma pa-
tients. We show that baseline levels of this panel of bio-
markers have implications in terms of OS and RFS.
Methods
Study design and patients
Banked baseline serum samples from 40 patients partici-
pating in the Eastern Cooperative Oncology Group–led
intergroup E1694 trial and treated with the GMK vaccine
were utilized for this analysis [18]. E1694 was a phase III
randomized study of vaccination with GMK (GM2-KLH/
QS-21, Progenics, Inc., Tarrytown, NY) versus HDI for
resected high-risk cutaneous melanoma patients (defined
as T4 > 4 mm primary lesions, or any primary lesion ac-
companied by regional lymph node metastasis). Patients
who were assigned to the vaccine group received GMK
vaccination up to 12 times over a 2-year period. All pa-
tients had an Institutional Review Board approved written
informed consent obtained.
Procedures
Using standardized phlebotomy procedures, up to 30 ml
of peripheral blood was drawn from each of the patients.
Samples utilized in this study were obtained from subjects
after study enrollment but prior to treatment initiation
(baseline). Blood samples were collected without anti-
coagulant into red top vacutainers and allowed to coagu-
late for 20-30 minutes at room temperature. Sera were
separated by centrifugation, and all specimens were imme-
diately aliquoted, frozen and stored in a dedicated−80°C
freezer. No more than 2 freeze-thaw cycles were allowed
before testing for each sample [18].
The Aushon Multiplex Platform (Aushon Biosystems,
Billerica, MA) was used to simultaneously quantitate the
serum levels of 115 candidate analytes. The assay com-
prises a multiplex sandwich ELISA of monoclonal capture
antibodies spotted in custom planar arrays in 96-well
micro-titer plates. After serum incubation and washing, a
second biotinylated monoclonal antibody to a different site
from the capture epitope was introduced and streptavidin-
horseradish peroxidase (HRP) was subsequently bound to
the biotin site. Luminol Enhancer/Peroxidase solution was
added and the HRP catalyzed the oxidation of luminol to
Figure 1 Kaplan-Meier plot of relapse free survival (RFS) by
baseline TNF-RII. High baseline levels of TNF-RII, dichotomized at
the median, are significantly associated with worse RFS (p = 0.01).
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chemiluminescent image was acquired and processed using
a 4-parameter curve fit program (SearchLight Array Ana-
lyst Software) to compare the experimental sample values
to a recombinant calibration curve run in parallel wells to
derive absolute concentrations adjusted for dilution and
quality values.
The analystes tested were human IL-6, IL-7, IL-10, IL-
16, TNF alpha trimer, IL-1 beta, IFN alpha, IL-4R, IL-18,
RANK-L, IL-1 alpha, IL-2R, IL-6R, MPIF-1, Leptin,
MIG, GDNF, MIP-1 alpha, MIP-1 beta, MIP-1 delta,
ITAC, GM-CSF, MCP-4, MIP-3 alpha, MIP-3 beta,
MMP-1, SP-C, Amphiregulin, RANK, MCP-2, IP-10,
OPG, FGF basic, KGF, HGH, GCSF, MMP-8, MMP-13,
TGF alpha, TGF beta 1, TGF beta 2, TRAIL, TARC,
MDC, Eotaxin-2, Beta Defensin 2, GRO gamma, TPO,
HGF Beta, NGF, ErbB2, EGF, E-Selectin, P-Selectin, E-
Cadherin, PAPP-A, VEGF-R1, VEGF- R2, PECAM-1,
MCP-1, c peptide, CD40L, TSP-2, H-CC4, BDNF, RAGE,
sAPPb, Thrombomodulin, ENA-78, GRO alpha, CD30,
ICAM-3, MMP-7, CG alpha, IL-1RII, TNF-RII, IGFBP-3,
EGFR, Human Resistin, MMP-9, ICAM-1, VCAM-1,
PAI-1 total, IgE, MPO, TIMP-1, TIMP-2, PDGF-AA,
NGAL, Acrp-30, MIP-4/PARC, SHBG, CD14, Clusterin,
CRP, NAP-2, Fibronectin, PDGF-BB, VEGF-D, VEGF,
TWEAK, PDGF-AB, M-CSF, SDF-1 beta, OPN, Ang-2,
IL-17A, RBP4, alpha-2 macroglobulin, Apo-A1, Von
Willebrand Factor, A-SAA, IL-23, Visfatin, Fibrinogen.
Statistical analysis
Univariate proportional hazard (PH) models were used to
assess the association between each marker and OS or
RFS. The Benjamini and Hochberg’s method was used to
adjust for multiple testing. Markers with detection rate <
70% were dichotomized as detected versus not detected.
The least absolute shrinkage and selection operator pro-
portional hazard regression (Lasso PH) was used to select
markers that are most informative for RFS and OS [21].
Markers with fitted coefficients ≥ 0.1 were selected. We
then fitted the regular PH models using the markers se-
lected by the Lasso PH. The survival receiver operating
characteristic (ROC) analysis was used to evaluate the
ability of the models to predict 1-year RFS and 5-year OS
[22]. Leave-one-out cross validations (LOOCVs) were used
to avoid over fitting.
Results
A panel of four markers that include Tumor Necrosis
Factor alpha Receptor II (TNF-RII), Transforming Growth
Factor alpha (TGF-α), Tissue Inhibitor of Metalloprotein-
ases 1 (TIMP-1), and C-reactive protein (CRP), at baseline
was found to be most informative for OS (high serum
levels correlate with worse prognosis). While only TNF-
RII was significantly associated with RFS.RFS analysis
TNF-RII was selected as the only main contributor for
RFS among the markers tested. We used the Cox PH
model with TNF-RII as a predictor for 1 year RFS using
survival ROC analysis [22]. We achieved an area under the
curve (AUC) of 76% with the full dataset; however, the
cross-validated AUC was 66%. High baseline levels of
TNF-RII, dichotomized at the median, were significantly
associated with worse RFS (log rank test p–value = 0.01).
Figure 1 shows the Kaplan-Meier (K-M) plot of RFS by
baseline TNF-RII.
OS analysis
Markers with Lasso coefficients >0.1 were included in the
final model. The panel of markers that were selected in-
cluded TGF-α, TNF-RII, TIMP-1 and CRP. The three
markers that were most reliable were TNF-RII, TIMP-1
and CRP (being selected by the model most of the time
during the cross validation). The survival ROC analysis
demonstrated that the Cox PH model using these four
markers predicts the 5 year OS well with an AUC for the
full dataset of 88% and a cross-validated AUC of 72%. Di-
chotomizing the linear score by the Cox PH model, at the
median, was significantly predictive of OS (log rank test p-
value = 0.0005). The K-M plot for the dichotomized score
by the Cox PH model is shown in Figure 2.
Discussion
Among populations of patients with melanoma at high
risk after surgical resection, efforts to identify subsets of
patients at relatively higher risk for melanoma recur-
rence and mortality are warranted. These may have clin-
ical prognostic implications, and may drive the design of
future adjuvant trials by enabling us to stratify treatment
Figure 2 Kaplan-Meier plot of overall survival by baseline
TGF-α, TNF-RII, TIMP-1, CRP (Cox PH model score). High serum
levels correlate with worse prognosis.
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be more likely to benefit from adjuvant interventions.
Patients treated on the GMK vaccine arm of E1694 are
ideal candidates for studies of baseline prognostic bio-
markers given the lack of any demonstrable impact this
vaccine has shown in terms of either RFS or OS in large
randomized controlled multicenter cooperative group
trials [6,18,19]. In E1694, the ganglioside GMK vaccine
is now therefore considered a control arm of this study,
where the clinical outcome showed significant advantage
in favor of HDI in an intent-to-treat analysis analysis of
both RFS and OS [18]. The GMK vaccine was also evalu-
ated as an arm of the E2696 study which was a random-
ized phase II trial that enrolled patients with resected
stage IIB, stage III, and stage IV disease [6]. Here again,
GMK appeared to have no impact on RFS or OS of pa-
tients treated on the trial, whether administered as
monotherapy or in combination with HDI [6]. Most re-
cently, the EORTC 18961 trial tested the post-operative
adjuvant benefit of ganglioside GM2-KLH21 vaccination
treatment versus observation in stage II (T3-T4N0M0)
melanoma patients, demonstrating the absence of any
significant effect of this vaccination upon either of the
primary outcomes of RFS or OS [19].
We have therefore conducted a multiplex analysis of
115 candidate serum analytes in patients treated with the
GMK vaccine in E1694. Our modeling analysis has shown
that the four-marker panel consisting of TNF-RII, TGF-α,
TIMP-1, and CRP, at baseline was found to be most
informative in regard to OS where high serum levels cor-
relate with worse prognosis. In addition, high baseline
TNF-RII was also identified as the most informativemarker in relation to worsened RFS. The RFS of patients
with high (above median) baseline levels of TNF-RII was
significantly lower than that of patients with low (below
median) baseline TNF-RII (log rank test p-value = 0.01).
TNF-α is a proinflammatory cytokine that plays a cen-
tral role in inflammation [23]. It mediates its activities
through two cell surface receptors, TNF-RI and TNF-RII
that are active in soluble and in membrane-bound forms,
and TNF-RII has been shown to have a higher affinity for
TNF-α [24]. TNF-RI is constitutively expressed in most
tissues while TNF-RII is expressed predominantly on im-
mune cells and endothelial cells [25]. The soluble forms of
the receptors have been reported to act as physiological at-
tenuators of TNF-α activity [26], where the shedding of
TNF-Rs leads to diminished surface receptors and this
process has been proposed to reduce the clinical activity
resulting from TNF-α in rheumatoid arthritis [27]. There-
fore, it is reasonable to hypothesize that high circulating
levels of TNF-RII may attenuate the proinflammatory ef-
fects of TNF-α in patients with cancer as part of an overall
state of immune tolerance. Further testing of TNF-RII as a
potential prognostic marker in patients with high risk mel-
anoma is warranted.
TGF-α is upregulated in several human cancers [28],
including melanoma [29]. It is a polypeptide growth-
stimulating factor that has been implicated in the pro-
gression of gastrointestinal cancers. In addition, serum
TGF-α was found to be significantly elevated in patients
with gastric, pancreatic, colon, rectal and esophageal
cancers as compared with healthy controls [28]. In mel-
anoma, transcriptional upregulation of TGF-α has been
associated with differentiation of human melanoma
cells [30]. TGF-α belongs to the epidermal growth factor
(EGF) family of mitogens [31]. EGF and TGF-α have
closely related tertiary structures and they compete for
binding to the EGF-receptor which has been shown to be
overexpressed in melanoma cells [31]. The potential prog-
nostic value of high serum levels of TGF-α in high risk
melanoma patients at poorer prognosis should therefore
be further evaluated as supported by our findings.
TIMPs are encoded by four genes designated TIMP-1,
TIMP-2, TIMP-3, and TIMP-4 [32]. They are potent
regulators of the proteolytic activity of matrix metallo-
proteinases [33]. TIMP-1 was shown to have cell growth
promoting properties in a variety of cancer cell lines in-
cluding breast carcinoma cells and leukemic cell lines
[32]. In addition, TIMP-1 was reported to have anti-
apoptotic properties [34], and to have a role as a promo-
tor of cell differentiation [32]. Significantly increased
serum TIMP-1 levels and a potential poor prognostic
role have been reported in patients with melanoma [35],
and patients with a variety of cancer types including
breast [36,37], prostate [38], gastric [39], colorectal car-
cinoma [40], glioblastoma [41], and multiple myeloma
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were found to be significantly higher in patients with
unresected stage IV disease than in patients with
resected stage I/II [35]. In patients with non-small cell
lung cancer who underwent surgical resection with
curative intent, postoperative TIMP-1 has been reported
as an independent predictor of prognosis [44].
Data support a role for high serum CRP as a marker
of poor prognosis and of immune tolerance in advanced
melanoma [45]. For first detection of melanoma stage
IV disease, serum CRP has been reported to be poten-
tially superior to serum LDH measurement [46]. As
interesting, is a potential role for CRP in mediating im-
mune tolerance: CRP is synthesized by hepatocytes in
response to interleukin-6 during inflammation in con-
centrations that vary between non-tolerogenic and tol-
erogenic levels. There is a physiological role of “ectopic”
thymic expression in tolerance induction by CRP (and
other acute-phase proteins) and possibly other inducible
self-antigens [47,48]. CRP binds to phosphocholine
(PC) and related molecules on microorganisms and
plays an important role in host defense. Further, an im-
portant effect may relate to the binding of CRP to PC in
damaged membranes. CRP increases clearance of apop-
totic cells, binds to nuclear antigens and by masking
autoantigens from the immune system or enhancing
their clearance, CRP has been hypothesized to prevent
autoimmunity [47]. Baseline (pre-treatment) serum
CRP was reported to have a potential therapeutic pre-
dictive value in melanoma patients treated with the
anti-CTLA4 antibody tremelimumab [49,50].
Our systematic modeling analysis starting with the 115
markers tested utilizing baseline biospecimens identified
the signature of four markers discussed (TNF-RII, TGF-α,
TIMP-1, and CRP) where the linear combination gener-
ates a risk score that is significantly prognostic of worse
survival in this patient population. The ROC analysis has
further supported the survival predictive ability of the
model. Further characterization and validation of this as-
sociation for the individual markers as well as the four
markers signature is indicated both in terms of clinical ap-
plications as markers of poor prognosis in patients with
high risk melanoma after surgical resection and in the de-
sign of future adjuvant trials as stratification factors once
validated.Conclusion
The four serum biomarker signature consisting of TNF-
RII, TGF-α, TIMP-1, and CRP as measured at baseline is
significantly prognostic of worse survival in high risk
melanoma patients and warrants further investigation as
a marker of poor prognosis that my guide patient follow
up and the design of future adjuvant studies.Abbreviations
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